Table 3.

Cost Effectiveness Analysis

Screening Strategy	Total Cost	Cases of PID Expected	Incremental Costs	Incremental Cases of PID Prevented	Incremental Cost-Effectiveness Ratio (ICER)
Endocervical DNA probe*	$636,913	115	—	—	—
Endocervical AC2	$627,204	44	−$9709	71	−$137
First catch urine AC2	$613,732	44	−$13,472	0	−$13,472†
Self obtained vaginal AC2	$573,205	27	−$40,527	17	−$2384

^*DNA Probe was PACE2 Assay.

^†Division by 0 results in infinity, therefore, divided −$13,472 by 1.

AC2 indicates Aptima Combo 2.